Blockchain Registration Transaction Record

Kairos Pharma to Reveal Prostate Cancer Drug Trial Results Sept 18

Kairos Pharma announces Sept 18 event to discuss Phase 2 trial results for ENV105 in advanced prostate cancer, focusing on overcoming drug resistance through innovative antibody therapy.

This development matters because prostate cancer remains one of the most common cancers in men worldwide, with advanced stages often developing resistance to existing treatments. The ENV105 compound represents a novel approach to overcoming treatment resistance, which could potentially extend survival and improve quality of life for patients facing limited options. Successful results from this trial could lead to new combination therapies that address the critical challenge of drug resistance in oncology, potentially benefiting not only prostate cancer patients but also those with other cancers where CD105-mediated resistance occurs.